Gilead(US:GILD) ZACKS·2025-10-30 22:16分组1 - Gilead Sciences reported quarterly earnings of $2.47 per share, exceeding the Zacks Consensus Estimate of $2.15 per share, and showing an increase from $2.02 per share a year ago, resulting in an earnings surprise of +14.88% [1] - The company achieved revenues of $7.77 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 4.16%, and up from $7.55 billion year-over-year [2] - Gilead has outperformed the S&P 500 with a stock increase of about 28.3% since the beginning of the year, compared to the S&P 500's gain of 17.2% [3] 分组2 - The earnings outlook for Gilead is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is $2.03 on revenues of $7.6 billion, and for the current fiscal year, it is $8.07 on revenues of $28.8 billion [7] - The Medical - Biomedical and Genetics industry, to which Gilead belongs, is currently ranked in the top 38% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]